Company / SG&A per Share
Halozyme SG&A per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$1.68
FY2025
5-year range
$0.57 / $1.68
FY2021-FY2025
Trend
+38.1%
vs FY2024
Sector context
#88 of 210
Health Care
What the data says
At $1.68, Halozyme's sg&a per share ranks #123 of 210 in the Health Care sector. SG&A per Share has increased for 6 consecutive years, from $0.37 in FY2019 to $1.68 in FY2025.
Based on SEC 10-K filings.
1.68 in FY2025 with a 5-year CAGR of +30.5%.
Increased from $1.10 to $1.68 over the past 2 years.
Health Care sector context is included.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- +17.2%
- 5-Year CAGR
- +30.5%
- 10-Year CAGR
- -
Sector benchmark
#123 of 210 in Health CareTop 58% of 210This company $1.68 Sector average $29.50
▼
-94.3% below sector average
Key checks
Key Insights
- Halozyme's sg&a per share has grown for 6 consecutive years.
- In FY2025, sg&a per share increased 38.1% year-over-year.
- Ranks #88 out of 210 companies in the Health Care sector.
- Lowest sg&a per share in the period was in FY2016.
Company context
Key Data Points
- Strong profit margin: 47.9%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 118.2%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.68 | +38.1% |
| FY2024 | $1.22 | +10.3% |
| FY2023 | $1.10 | +5.7% |
| FY2022 | $1.04 | +82.5% |
| FY2021 | $0.57 | +28.6% |
| FY2020 | $0.44 | +19.6% |
| FY2019 | $0.37 | -12.7% |
| FY2018 | $0.43 | +2.5% |
| FY2017 | $0.42 | +48.2% |
| FY2016 | $0.28 | +9.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026